Thus, our study design ensured the elimination of several confounding factors (gender diversity, cannabis influence, study design based on mGluR5/glutamate system variations) that were not considered in some other previous studies investigating the glutamatergic system in schizophrenia. The gene discussed is GRM5; the disease is schizophrenia.